Clinical benefits of cytokine blockade in ileal Crohn's disease (iCD) are limited to a subset
of patients. Here, we applied single-cell technologies to iCD lesions to address whether …

Background & Aims Phase 3 trials have shown the efficacy of vedolizumab, which binds to
integrin α4β7, in patients with Crohn’s disease (CD) or ulcerative colitis (UC). We investigated …

Background In Europe, gastric cancer remains diagnosed at advanced stage (serosal and/or
lymph node involvement). Despite curative management combining perioperative systemic …

OBJECTIVES: The objective of this study was to evaluate short-and long-term outcomes of
infliximab in ulcerative colitis (UC), including infliximab optimization, colectomy, and …

OBJECTIVES: We sought to determine the frequency of and risk factors for early (30-day)
postoperative complications after ileocecal resection in a well-characterized, prospective …

Background We recently showed that vedolizumab is effective in patients with Crohn's disease
(CD) and ulcerative colitis (UC) with prior anti‐TNF failure in a multicentre compassionate …

Objectives: Fecal calprotectin (fCal) is widely used as marker of gut inflammation and is
strongly associated with the severity of endoscopic lesions in Crohn’s disease (CD). We …

… Dr Nicolas Williet, Gilles Boschetti, Hubert marotte, Anne Berger and Jean marc Phelip G
have no conflict of interest to declare; Stephane Paul was speaker for Theradiag, MSD. Dr …

Background & Aims We investigated whether serum trough levels of vedolizumab, a humanized
monoclonal antibody against integrin α4β7, during the induction phase of treatment can …

Background The effectiveness of vedolizumab as a treatment for extraintestinal
manifestations ( EIM ) is questionable due to its gut‐specificity. Aim To assess effectiveness of …